EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share
|
EQS-News: BB BIOTECH AG
/ Key word(s): AGM/EGM/Dividend
Media release of March 19, 2026 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a dividend of CHF 2.25 gross per share. Payment will be made on March 25, 2026, the record date is March 24, 2026 and the ex-dividend date is March 23, 2026. Shareholders re-elected the previous board members Dr. Thomas von Planta (Chairman), Prof. Dr. Mads Krogsgaard Thomsen, Laura Hamill, Dr. Pearl Huang and Camilla Soenderby for another one-year term of office.
Head BB Biotech Team Investor Relations Media Relations
www.bbbiotech.com
Company profile
19.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2294558 |
| End of News | EQS News Service |
|
|
2294558 19.03.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 683,90 | 0,00 | 1,28 | 0,57 | 119,28 | 663,55 | 0,00 | |
| EBITDA1,2 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 622,08 | 0,00 | |
| EBITDA-Margin3 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 93,75 | 0,00 | |
| EBIT1,4 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 622,08 | 0,00 | |
| EBIT-Margin5 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 93,75 | 0,00 | |
| Net Profit (Loss)1 | 637,24 | -390,53 | -362,83 | -222,41 | 80,66 | 622,01 | 0,00 | |
| Net-Margin6 | 93,18 | 0,00 | -28.346,09 | -39.019,30 | 67,62 | 93,74 | 0,00 | |
| Cashflow1,7 | 241,97 | -91,44 | 234,37 | 234,97 | 323,67 | 332,61 | 0,00 | |
| Earnings per share8 | 11,51 | -7,05 | -6,59 | -4,05 | 1,47 | 11,34 | 4,30 | |
| Dividend per share8 | 3,32 | 3,67 | 2,88 | 2,10 | 1,91 | 2,46 | 2,05 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BB Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0NFN3 | CH0038389992 | AG | 2.767,23 Mio € | 10.12.1997 | Kaufen | 8FVCMJWM+W3 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 11,10 | 9,65 | 1,15 | 19,79 | 0,97 | 8,32 | 4,17 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 2,10 | 1,91 | 2,46 | 4,92% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2026 | 24.04.2026 | 24.07.2026 | 23.10.2026 | 20.02.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -1,00% | +18,52% | +2,99% | +35,92% | +951,58% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
